Atai Life Sciences N.V. (ATAI)

atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Atai Life Sciences N.V. (NASDAQ:ATAI ) H.C.

atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement a...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has reflected on a “transformational” first half of 2025, marked by a series of clinical and corporate milestones, including positive topline data from its Ph...

Despite the phase 2b failure of inidascamine for CIAS, I maintain a Buy on Atai due to its diversified psychedelic pipeline. Beckley Psytech's BPL-003 drug for treatment-resistant depression showed st...

Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said on Friday that its platform company, Recognify Life Sciences, reported top-line results from a Phase 2b trial of inidascamine in cognitive impairment ass...

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.

Atai Life Sciences and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with cognitive impairment linked to schiz...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and es...